CompletedNot Applicable

SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC

China238 participantsStarted 2022-06-01

Plain-language summary

This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitors (TACE-L-P) in patients with HCC beyond up-to-seven criteria or with portal vein tumor thrombus (PVTT). Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the two groups.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * histologically or clinically confirmed diagnosis of HCC at BCLC stage B or C (extrahepatic metastases were allowed) * Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 * Child-Pugh class A or B7 * unresectable HCC with intrahepatic tumor beyond up-to-seven criteria and/or with PVTT. Exclusion Criteria: * receipt of other loco-regional therapies, including hepatic arterial infusion chemotherapy, external radiation therapy, or radioactive seed implantation * Prior systemic therapy * History of other malignancies * incomplete medical records

What they're measuring

Progression-free survival

Timeframe: 32 months

Trial details

NCT IDNCT06916546

SponsorSecond Affiliated Hospital of Guangzhou Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-31

View on ClinicalTrials.gov More Hepatocellular Carcinoma Non-resectable trials